Back to today’s briefing

Story perspectives

Pfizer, Valneva Seek Approval for Lyme Vaccine Despite Efficacy Setback

3/23/2026

38 7 Full Breakdown

Summary

Story summary

Pfizer, Inc., and Valneva SE plan to seek regulatory approval for their Lyme disease vaccine after a late-stage trial missed its primary efficacy goal.
The vaccine showed 73.2% efficacy.
Fewer cases than expected complicated the results.
Annaliesa Anderson, Pfizer's Chief Vaccines Officer, expressed confidence.
If approved, it would be the first human Lyme disease vaccine since LYMErix was withdrawn in 2002, with a planned launch in late 2027.

1 of 1

Story summary

Pfizer, Inc., and Valneva SE plan to seek regulatory approval for their Lyme disease vaccine after a late-stage trial missed its primary efficacy goal.
The vaccine showed 73.2% efficacy.
Fewer cases than expected complicated the results.
Annaliesa Anderson, Pfizer's Chief Vaccines Officer, expressed confidence.
If approved, it would be the first human Lyme disease vaccine since LYMErix was withdrawn in 2002, with a planned launch in late 2027.